Co-Diagnostics Corp - רווח נקי למניה בארבעת הרבעונים האחרונים CODX

Co-Diagnostics, Inc. (CODX) is protected by CoPrime patents and strict FDA compliance. The rolling annual EPS YoY trend on the GURU.Markets base chart links these barriers to revenues from test system sales, where 33.90 expresses the current value of the metric. Meanwhile, Co-Diagnostics, Inc. (CODX) is combating post-pandemic customer churn by diversifying its diagnostics into veterinary medicine and tuberculosis treatment.
פילוחי מדדים פיננסיים ומדדי שוק עבור CoDx (CODX)

Against the backdrop of Co-Diagnostics, Inc. (CODX) transforming its business model toward universal IT platforms, the rolling year-over-year (YoY) change in earnings per share allows for an assessment of the company's effectiveness in overcoming the demand crisis for PCR tests. This metric measures the percentage growth in net income over the last 12 months relative to the same period last year, demonstrating to the investor the real dynamics of return on equity amid a structural rebalancing of assets.